Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No chance, they are spamming .
If someone had bought £20k, we would not be negative.
£20k PYC ?
Discodog.. Did you buy PYC as well??!!
I have purchased £20,000 this morning
Top 2 small caps for re rate
CPX and RQIH
Thankyou debull and phenix
The alignment of this initiative with Physiomics expertise is so in sync. The history and experience of Physiomics along with the exposure senior members of the team have had to influential players in the industry is very encouraging.
Peter has taken a little time to bed in, but is starting to position Physiomics to maximise on these opportunities. Improved communication should follow and we should continue to see positive signs for patients, the oncology ecosystem and shareholders alike.
Exciting times ahead for sure.
CO funded by NIHR & Prostate Cancer UK to.
Https://www.icr.ac.uk/news-archive/new-screening-trial-to-save-thousands-of-men-s-lives-from-prostate-cancer#:~:text=TRANSFORM%20will%20test%20new%20approaches,and%20many%20thousands%20more%20worldwide.
PYC have links to ICR and Royal Marsden to.
With Peters background you would think he could
Put PYC at forefront on UK cancer initiatives
Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK
I posted the last few paragraphs,I wonder if PYC A.I dosing tool found be innthe frame to help ?
https://www.dailymail.co.uk/health/article-13367687/amp/UK-prostate-cancer-trial-screening-programme-death-40.html?ico=amp_articleInlineText
The unreliability of the PSA test is why as yet, there is no national screening programme, despite 142 men a day in the UK being diagnosed with the disease.
Designed in consultation with the UK NSC and National Institute for Health and Care Research (NIHR), it is hoped the TRANSFORM trial will provide the evidence needed to get it over the line to join breast, cervical and bowel cancer screening.
Rakesh Heer, a clinician and Professor of Urology at Imperial College London who is also involved in the trial said: 'TRANSFORM is not only the most important diagnosis trial in more than two decades, but it could also prove a game changer for prostate cancer research as a whole.
'This treasure trove will help researchers around the world create and validate innovative new tests, treatments, and AI tools.'
More volume and this is mid 2’s /3’s
Upwards hard to buy this morning again
Very impressive Ant
You really ARE convinced !!
I only experienced a little difficulty today but have taken my holding up to 1.7% over the last 20 days and will be buying more Laura.
Seems to be difficult to buy any real quantity again
Fully agreed on this one…I’d expect news promptly
Although I'd expect to hear something now the 2 conferences have finished
Old 1!!
I was looking at old RNS's an that 1 was at the top, forgot to refresh......doh
Isn't that an old one ?
Https://www.londonstockexchange.com/news-article/PYC/contract-award/15710389
Many thanks Ant
Very reassuring that someone with your expertise rates PYC
"y" not "t" in my last post "busy." clumsy fingers! Its a convoluted story but on a completely different company I was able to forge a bond some years earlier with Main Board Merck Directors that facilitated the first contract for PYC.
I am looking forward to a greater uptake of the technology following the FDA ruling in December 2022 when their latest ACT required the use in part of computer based modelling for drug approval in a move away from animal testing. These things take time to gain traction but I am as sure as I can be that these pressures will now be ramped up by the FDA who will insist on the same and ever increasingly. Not before time as animal rights protestors ( quite justifiably ) have long protested against the use of animals in clinical trials. The technology is out there PYC have a meaningful offering to Pharma Co's. Now is the time to invest in accurate predictive technology as it is rapidly moving to a "must Have " as opposed to a" may be" on a wish list. It will be interesting to see the outcome of their recent presentations. Ant
As an aside poster/investors might want to write on some of the protestors sites promoting PYC as an alternative, they are extremely proactive and not without influence!
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has disclosed that it is a customer of Physiomics. Merck & Co. published a paper in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process
Debull
Nothing to apologise for as I had no idea pyc worked with both